A problem with traditional mAb manufacturing is that there are so many potential entry points for microbial contamination. There are, however, ways to shut the door on contamination.
The risk is most acute in the upstream process, which should not be a surprise. What better place for a bacterial contamination to grow than in a well-aerated, nutrient-loaded cell culture medium? Downstream operations also have their share of risk. The open handling introduces many potential bioburden entry points.
In this new blog-article, potential bioburden sources in bioprocessing are discussed and ways to address the risks.